QuantuMDx receives CDTA approval for sale of Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay
December 13, 2022 02:00 ET
|
QuantuMDx Group Ltd
QuantuMDx receives CDTA approval for sale of Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay NEWCASTLE UPON TYNE, UK 13 December, 2022. QuantuMDx Group Limited (“QuantuMDx”), today announces that its...
QuantuMDx announces approval of its Rapid Q-POC™ SARS-CoV-2 assay in the UK under CTDA legislation
February 22, 2022 08:53 ET
|
QuantuMDx Group Ltd
QuantuMDx announces approval of its Rapid Q-POCTM SARS-CoV-2 assay in the UK under CTDA legislation NEWCASTLE UPON TYNE, UK, 22 February 2022. QuantuMDx Group Limited (“QuantuMDx”), today announces...
QuantuMDx confirm its diagnostic tests remain able to detect all known variants of COVID-19 including the new variant from South Africa, B.1.1.529
November 26, 2021 07:37 ET
|
QuantuMDx Group Ltd
NEWCASTLE UPON TYNE, UK, 26 NOVEMBER 2021. QuantuMDx Group Limited (“QuantuMDx”), today confirms that both its SARS-CoV-2 assays for open PCR platforms and its rapid PCR device, Q-POC™, as well as its...
QuantuMDx partners with Cignpost Diagnostics
August 16, 2021 02:00 ET
|
QuantuMDx Group Ltd
QuantuMDx partners with Cignpost Diagnostics Providing a rapid, PCR COVID-19 testing solution to the UK film & TV industry NEWCASTLE UPON TYNE, UK, 16 August 2021. QuantuMDx Group Limited has...
QuantuMDx launches Q-POC™ - rapid PCR point of care diagnostic system
July 09, 2021 02:00 ET
|
QuantuMDx Group Ltd
QuantuMDx launches Q-POC™ - rapid PCR point of care diagnostic system Roll out at ECCMID 2021 with Q-POC™ SARS-CoV-2 assay96.9% sensitivity, 98.3% specificitySample to result - approximately 30...
Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx
February 13, 2021 10:30 ET
|
QuantuMDx Group Ltd
Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx - QuantuMDx has developed Q-POC™ - a rapid, PCR diagnostic device for coronavirus testing at the point of...